SecBot SecBot
8-K ·Filed Nov 10, 2026

MTRI

InMed Pharmaceuticals Inc.
MIXED
Impact 7/10
Horizonimmediate Processed6d 10h ago SEC0001193125-26-455640
Killer combo: M&A completed + management change
Actionable Insight ◆ Mixed

Monitor the combined company's progress in migraine prevention clinical programs (MT-001, MT-002) and any CVR-related monetization of InMed's legacy cannabinoid assets. The $490M cash position provides runway for development.

DirectionMixed
Confidencehigh
Horizonimmediate

Drugs in focus

MT-001

● Neutral Named in this 8-K
Impact
Phase
Preclinical (IND-enabling)
Time to market
Unknown — still preclinical. If successful through Phases 1-3, a potential approval would be 5+ years away.
Next catalyst
None dated

What to watchMT-001 is too early for a binary trade, no human data exists yet and Phase 2a data is two+ years out. The real near-term story for INM is the reverse-merger close (expected by Dec 31, 2026) and whether the $290M PIPE fully funds through 2028 as promised. Post-merger the ticker changes, so current INM holders are effectively buying Mentari's preclinical pipeline at the merged entity's valuation. Watch for the IND/CTA filing mid-2026 as a first proof of life.

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$15.61
T+0 close · Nov 10, 2026 · via day close
Latest settled
+17.56%
T+1 · $18.35
Vs SPY
+17.91%
α at T+1
Next horizon
T+5
tomorrow
  1. T+0 · Nov 11 $15.61entry
  2. T+1 · 5d ago +17.56%α +17.91% · $18.35
  3. T+3 · todayOpen
  4. T+5 · tomorrow Pending
  5. T+20 · in 23d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

InMed Pharmaceuticals completed its reverse merger with Mentari Therapeutics on November 6, 2026, with Mentari as the accounting acquirer. Former InMed shareholders received contingent value rights (CVRs) for legacy assets, while Mentari shareholders and PIPE investors own approximately 99% of the combined company. The combined company, renamed Mentari Therapeutics, Inc., will focus on migraine prevention therapies.

Key Financial Metrics

Deal Type
merger
Offering Size
$490.0M

Key Facts

  • Merger closed on November 6, 2026; InMed changed name to Mentari Therapeutics, Inc.
  • Former Mentari stockholders own ~99% of combined company; InMed stockholders ~1%
  • Mentari raised $490M in pre-closing financing (First Pre-Closing $290M, Second $200M)
  • Exchange ratio: 0.20065 shares of InMed common stock per Mentari share
  • InMed legacy assets (INM-901, INM-089, INM-755) placed into CVR structure for shareholders
  • Combined company focused on migraine prevention; Mentari management team leads
  • Fiscal year changed from June 30 to December 31
  • Board reconstituted with 5 members; Julianne Bruno appointed Chair
  • 2026 Stock Incentive Plan approved with initial pool of 9,618,697 shares
  • Company ceased to be a shell company as of the closing date

Financial Impact

Mentari raised $490M in pre-closing financing; combined company pro forma cash ~$478M as of June 30, 2026

cashownershiprevenuedilution

Risk Factors

  • CVR holders may never receive any proceeds from legacy asset monetization
  • Combined company has no approved products and is pre-revenue
  • Integration risks and potential for higher-than-expected transaction costs
  • Dependence on Paragon Therapeutics for antibody discovery and manufacturing
  • document contains text addressed to automated readers

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-455640
Document: d539218d8k.htm0001193125-26-455640
Document: d539218dex107.htm0001193125-26-455640
8-K Data (Synthetic)0001193125-26-455640

US Market Status

Market Closed · Opens in 6h 8m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026